NEW YORK – Investigators from the 23andMe Research Institute have identified genetic contributors to the weight loss effects or side effects associated with drugs that target the GLP1 receptors alone or in combination with gastric inhibitory polypeptide (GIP) hormone receptor targeting.
Already a GenomeWeb member? LoginLogin
Get the full story with GenomeWeb Premium
Only $95 for the first 90 days
Benefits:
Full site access
Interest-based email alerts
Access to archives
Premium Access - Trial Offer
$95.00 for 3 month
Benefits:
Full site access
Interest-based email alerts
Access to archives
Already a GenomeWeb member? LoginLogin
